Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer1
INTRODUCTION : The aim of the present study was to analyze the possible correlation between Natural Killer (NK) cell activity as measured by the NK Vue assay and treatment efficacy in patients with disseminated cancer. MATERIALS AND METHODS : The study included four trials encompassing palliative tr...
Gespeichert in:
| Veröffentlicht in: | Translational oncology 2019-05, Vol.12 (7), p.968-972 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 972 |
|---|---|
| container_issue | 7 |
| container_start_page | 968 |
| container_title | Translational oncology |
| container_volume | 12 |
| creator | Hansen, Torben Frøstrup Nederby, Line Zedan, Ahmed H. Mejlholm, Inge Henriksen, Jon R. Steffensen, Karina D. Thomsen, Caroline B. Raunkilde, Louise Jensen, Lars Henrik Jakobsen, Anders |
| description | INTRODUCTION
: The aim of the present study was to analyze the possible correlation between Natural Killer (NK) cell activity as measured by the NK Vue assay and treatment efficacy in patients with disseminated cancer.
MATERIALS AND METHODS
: The study included four trials encompassing palliative treatment, i.e. one trial on prostate- and ovarian cancer, respectively, and two trials on colorectal cancer. The current results are based on 93 patients with mature data on treatment effect. Blood samples were collected at baseline and prior to each treatment cycle into NK Vue. Following 24 hours of stimulation the level of interferon-gamma (IFNγ) in the plasma was measured as a surrogate for NK cell activity.
RESULTS
: The relationship between NK cell activity and treatment response was similar across tumor types and treatment. The IFNγ either remained at or dropped to an abnormal level (200 pg/mL), while in group 3 (n = 28) it increased from an abnormal to a normal level. The response rate was 14%, 47%, and 82%, respectively,
P
|
| doi_str_mv | 10.1016/j.tranon.2019.04.002 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6554227</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_6554227</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_65542273</originalsourceid><addsrcrecordid>eNqljc1Kw0AUhQdBbP15Axf3BRrnp0nIRtBYKQjiovtwTW7srZNJmblt6dubhRvXrg6cw_cdpe6Nzow2xcMuk4hhDJnVpsr0MtPaXqi5qVyxyK1zM3Wd0k7rwlTWXqmZM0a7sizn6rseYySPwmOAZ5ITUYB3lENED2_sPUWoyXt4aoWPLGfA0MEmEspAQWDV99QKcICPyTE1CU4sW3jhlGjggEId1BhaiuZWXfboE9395o16fF1t6vVif_gcqGsnenpt9pEHjOdmRG7-LoG3zdd4bIo8X1pbun8LfgCkDmgJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer1</title><source>PubMed Central</source><source>Directory of Open Access Journals</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Hansen, Torben Frøstrup ; Nederby, Line ; Zedan, Ahmed H. ; Mejlholm, Inge ; Henriksen, Jon R. ; Steffensen, Karina D. ; Thomsen, Caroline B. ; Raunkilde, Louise ; Jensen, Lars Henrik ; Jakobsen, Anders</creator><creatorcontrib>Hansen, Torben Frøstrup ; Nederby, Line ; Zedan, Ahmed H. ; Mejlholm, Inge ; Henriksen, Jon R. ; Steffensen, Karina D. ; Thomsen, Caroline B. ; Raunkilde, Louise ; Jensen, Lars Henrik ; Jakobsen, Anders</creatorcontrib><description>INTRODUCTION
: The aim of the present study was to analyze the possible correlation between Natural Killer (NK) cell activity as measured by the NK Vue assay and treatment efficacy in patients with disseminated cancer.
MATERIALS AND METHODS
: The study included four trials encompassing palliative treatment, i.e. one trial on prostate- and ovarian cancer, respectively, and two trials on colorectal cancer. The current results are based on 93 patients with mature data on treatment effect. Blood samples were collected at baseline and prior to each treatment cycle into NK Vue. Following 24 hours of stimulation the level of interferon-gamma (IFNγ) in the plasma was measured as a surrogate for NK cell activity.
RESULTS
: The relationship between NK cell activity and treatment response was similar across tumor types and treatment. The IFNγ either remained at or dropped to an abnormal level (<200 pg/mL) during treatment in group 1 (n = 35). In group 2 (n = 30) the level remained within a normal range (>200 pg/mL), while in group 3 (n = 28) it increased from an abnormal to a normal level. The response rate was 14%, 47%, and 82%, respectively,
P
< .001. The median progression free survival was 2.6 months (95% confidence interval (CI) 2.1–3.9), 10.0 months (95% CI 6.5–11.1), and 8.3 months (95% CI 6.5–8.7), respectively,
P
< .001 (log-rank).
CONCLUSION
: Patients lacking the ability to mount an immune response during the first 2 months of treatment have a poor prognosis, and their clinical benefit of the treatment is questionable.</description><identifier>EISSN: 1936-5233</identifier><identifier>DOI: 10.1016/j.tranon.2019.04.002</identifier><identifier>PMID: 31103777</identifier><language>eng</language><publisher>Neoplasia Press</publisher><subject>Original article</subject><ispartof>Translational oncology, 2019-05, Vol.12 (7), p.968-972</ispartof><rights>2019 The Authors 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554227/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554227/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53769,53771</link.rule.ids></links><search><creatorcontrib>Hansen, Torben Frøstrup</creatorcontrib><creatorcontrib>Nederby, Line</creatorcontrib><creatorcontrib>Zedan, Ahmed H.</creatorcontrib><creatorcontrib>Mejlholm, Inge</creatorcontrib><creatorcontrib>Henriksen, Jon R.</creatorcontrib><creatorcontrib>Steffensen, Karina D.</creatorcontrib><creatorcontrib>Thomsen, Caroline B.</creatorcontrib><creatorcontrib>Raunkilde, Louise</creatorcontrib><creatorcontrib>Jensen, Lars Henrik</creatorcontrib><creatorcontrib>Jakobsen, Anders</creatorcontrib><title>Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer1</title><title>Translational oncology</title><description>INTRODUCTION
: The aim of the present study was to analyze the possible correlation between Natural Killer (NK) cell activity as measured by the NK Vue assay and treatment efficacy in patients with disseminated cancer.
MATERIALS AND METHODS
: The study included four trials encompassing palliative treatment, i.e. one trial on prostate- and ovarian cancer, respectively, and two trials on colorectal cancer. The current results are based on 93 patients with mature data on treatment effect. Blood samples were collected at baseline and prior to each treatment cycle into NK Vue. Following 24 hours of stimulation the level of interferon-gamma (IFNγ) in the plasma was measured as a surrogate for NK cell activity.
RESULTS
: The relationship between NK cell activity and treatment response was similar across tumor types and treatment. The IFNγ either remained at or dropped to an abnormal level (<200 pg/mL) during treatment in group 1 (n = 35). In group 2 (n = 30) the level remained within a normal range (>200 pg/mL), while in group 3 (n = 28) it increased from an abnormal to a normal level. The response rate was 14%, 47%, and 82%, respectively,
P
< .001. The median progression free survival was 2.6 months (95% confidence interval (CI) 2.1–3.9), 10.0 months (95% CI 6.5–11.1), and 8.3 months (95% CI 6.5–8.7), respectively,
P
< .001 (log-rank).
CONCLUSION
: Patients lacking the ability to mount an immune response during the first 2 months of treatment have a poor prognosis, and their clinical benefit of the treatment is questionable.</description><subject>Original article</subject><issn>1936-5233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqljc1Kw0AUhQdBbP15Axf3BRrnp0nIRtBYKQjiovtwTW7srZNJmblt6dubhRvXrg6cw_cdpe6Nzow2xcMuk4hhDJnVpsr0MtPaXqi5qVyxyK1zM3Wd0k7rwlTWXqmZM0a7sizn6rseYySPwmOAZ5ITUYB3lENED2_sPUWoyXt4aoWPLGfA0MEmEspAQWDV99QKcICPyTE1CU4sW3jhlGjggEId1BhaiuZWXfboE9395o16fF1t6vVif_gcqGsnenpt9pEHjOdmRG7-LoG3zdd4bIo8X1pbun8LfgCkDmgJ</recordid><startdate>20190516</startdate><enddate>20190516</enddate><creator>Hansen, Torben Frøstrup</creator><creator>Nederby, Line</creator><creator>Zedan, Ahmed H.</creator><creator>Mejlholm, Inge</creator><creator>Henriksen, Jon R.</creator><creator>Steffensen, Karina D.</creator><creator>Thomsen, Caroline B.</creator><creator>Raunkilde, Louise</creator><creator>Jensen, Lars Henrik</creator><creator>Jakobsen, Anders</creator><general>Neoplasia Press</general><scope>5PM</scope></search><sort><creationdate>20190516</creationdate><title>Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer1</title><author>Hansen, Torben Frøstrup ; Nederby, Line ; Zedan, Ahmed H. ; Mejlholm, Inge ; Henriksen, Jon R. ; Steffensen, Karina D. ; Thomsen, Caroline B. ; Raunkilde, Louise ; Jensen, Lars Henrik ; Jakobsen, Anders</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_65542273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Original article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hansen, Torben Frøstrup</creatorcontrib><creatorcontrib>Nederby, Line</creatorcontrib><creatorcontrib>Zedan, Ahmed H.</creatorcontrib><creatorcontrib>Mejlholm, Inge</creatorcontrib><creatorcontrib>Henriksen, Jon R.</creatorcontrib><creatorcontrib>Steffensen, Karina D.</creatorcontrib><creatorcontrib>Thomsen, Caroline B.</creatorcontrib><creatorcontrib>Raunkilde, Louise</creatorcontrib><creatorcontrib>Jensen, Lars Henrik</creatorcontrib><creatorcontrib>Jakobsen, Anders</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hansen, Torben Frøstrup</au><au>Nederby, Line</au><au>Zedan, Ahmed H.</au><au>Mejlholm, Inge</au><au>Henriksen, Jon R.</au><au>Steffensen, Karina D.</au><au>Thomsen, Caroline B.</au><au>Raunkilde, Louise</au><au>Jensen, Lars Henrik</au><au>Jakobsen, Anders</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer1</atitle><jtitle>Translational oncology</jtitle><date>2019-05-16</date><risdate>2019</risdate><volume>12</volume><issue>7</issue><spage>968</spage><epage>972</epage><pages>968-972</pages><eissn>1936-5233</eissn><abstract>INTRODUCTION
: The aim of the present study was to analyze the possible correlation between Natural Killer (NK) cell activity as measured by the NK Vue assay and treatment efficacy in patients with disseminated cancer.
MATERIALS AND METHODS
: The study included four trials encompassing palliative treatment, i.e. one trial on prostate- and ovarian cancer, respectively, and two trials on colorectal cancer. The current results are based on 93 patients with mature data on treatment effect. Blood samples were collected at baseline and prior to each treatment cycle into NK Vue. Following 24 hours of stimulation the level of interferon-gamma (IFNγ) in the plasma was measured as a surrogate for NK cell activity.
RESULTS
: The relationship between NK cell activity and treatment response was similar across tumor types and treatment. The IFNγ either remained at or dropped to an abnormal level (<200 pg/mL) during treatment in group 1 (n = 35). In group 2 (n = 30) the level remained within a normal range (>200 pg/mL), while in group 3 (n = 28) it increased from an abnormal to a normal level. The response rate was 14%, 47%, and 82%, respectively,
P
< .001. The median progression free survival was 2.6 months (95% confidence interval (CI) 2.1–3.9), 10.0 months (95% CI 6.5–11.1), and 8.3 months (95% CI 6.5–8.7), respectively,
P
< .001 (log-rank).
CONCLUSION
: Patients lacking the ability to mount an immune response during the first 2 months of treatment have a poor prognosis, and their clinical benefit of the treatment is questionable.</abstract><pub>Neoplasia Press</pub><pmid>31103777</pmid><doi>10.1016/j.tranon.2019.04.002</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1936-5233 |
| ispartof | Translational oncology, 2019-05, Vol.12 (7), p.968-972 |
| issn | 1936-5233 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6554227 |
| source | PubMed Central; Directory of Open Access Journals; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Original article |
| title | Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer1 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T21%3A03%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlation%20Between%20Natural%20Killer%20Cell%20Activity%20and%20Treatment%20Effect%20in%20Patients%20with%20Disseminated%20Cancer1&rft.jtitle=Translational%20oncology&rft.au=Hansen,%20Torben%20Fr%C3%B8strup&rft.date=2019-05-16&rft.volume=12&rft.issue=7&rft.spage=968&rft.epage=972&rft.pages=968-972&rft.eissn=1936-5233&rft_id=info:doi/10.1016/j.tranon.2019.04.002&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_6554227%3C/pubmedcentral%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31103777&rfr_iscdi=true |